Year: 2015
Type: article
Institutions: University of Alabama at Birmingham, UAB Medicine, University of Pittsburgh, Mexican Social Security Institute, Icahn School of Medicine at Mount Sinai, National Institutes of Health, National Heart, Lung, and Blood Institute, Memphis VA Medical Center, University of Minnesota, Emory University, Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: cardiovascular risk management, type 2 diabetes, coronary artery disease, BARI 2D trial, survival, cardiovascular mortality, cardiovascular events, intensive medical therapy, HDL cholesterol, triglycerides, blood pressure, HbA1c, myocardial infarction, stroke, revascularization, coronary artery bypass grafting
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Sanofi, American College of Cardiology Foundation, Boston Scientific Corporation, Novo Nordisk, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Janssen Pharmaceuticals
OpenAlex ID: W1469193822
